KKR Sells 5M BridgeBio Shares at $77.42, Exits 5% Ownership

summarizeSummary

KKR sold 5 million BridgeBio shares at $77.415 each, cutting its stake to 4.7% and exiting 5% ownership. The sale closed August 17, 2026, with a 30-day lock-up on further sales.

check_boxKey Events · Ownership and Investor Activity · BBIO

• KKR Sells 5M Shares

  KKR Genetic Disorder L.P. sold 5,000,000 shares at $77.415 per share in an underwritten offering, generating approximately $387 million in gross proceeds.

• Ownership Falls Below 5%

  After the sale, KKR's aggregate beneficial ownership is 9,232,739 shares (4.7%), crossing below the 5% threshold and triggering this exit filing.

• 30-Day Lock-Up

  KKR agreed to a 30-day lock-up restricting further sales or hedging of BridgeBio shares, subject to certain exceptions.

• Preferred Stock Purchase

  An Alternative Vehicle managed by KKR purchased 133,900 shares of Series A Preferred Stock for $1,000 per share on July 1, 2026, convertible into 971,768 common shares.

auto_awesomeAnalysis · BBIO · Life Sciences

A major long-term investor, KKR Genetic Disorder L.P., sold 5 million shares of BridgeBio Pharma in an underwritten offering at $77.415 per share, generating approximately $387 million in gross proceeds. The sale closed on August 17, 2026, and reduced KKR's aggregate beneficial ownership to 9,232,739 shares, or 4.7% of the company, crossing below the 5% reporting threshold. This is a significant distribution by a sophisticated institutional holder, and the exit filing signals a reduced commitment to the stock. The offering was priced at a modest discount to the current market price of $80.00, and KKR has agreed to a 30-day lock-up, limiting near-term additional sales. The transaction follows a period of strong clinical and regulatory progress for BridgeBio, including FDA priority review for BBP-418 and a $1 billion convertible preferred financing in July 2026.